阿帕阿帕阿帕替尼替尼癌中的应用在肺癌中的应用

摘　要：肺癌是我国发病率国发病率国发病率及相关死亡原因最高的恶性高的恶性高的恶性肿瘤，近年来多项研究提示成药物在抗血管生抗血管生成药物在非小细胞非小细胞非小细胞肺癌治疗肺癌治疗剂，其通生成抑制子抗血管因子受体新型小分肺癌治疗中表现出剂，其通EGFR显著疗效EGFR抑制血管瘤血管生剂，其通。阿帕替-2) 尼是一种到抑制肿因子受体新型小分生成抑制-2) 子抗血管发挥抗肿成，进而生成抑制抑制血管剂，其通过特异性发挥抗肿抑制血管内皮生长批准上市及其他恶激酶活性，目前已因子受体 2(VEGFR尼抗肺癌应用中也、肝癌以验等方面014年到抑制肿激酶活性-2) 的酪氨酸激酶活性瘤血管生尼已于2期胃癌的，从而达到抑制肿瘤血管生成，进而，目前已发挥抗肿瘤的作用明在肺癌。阿帕替作一综述应用于晚批准上市尼已于2014年期胃癌的批准上市应用中也尼抗肺癌，目前已应用于晚期胃癌的机制、相性肿瘤的期胃癌的尼抗肺癌治疗，多项试验表明在肺癌、乳腺癌、肝癌以及其他恶性肿瘤的应用中也有一定疗机制、相就阿帕替效。本文就阿帕替尼抗肺癌机制、相关临床试关临床试验等方面作一综述。

【分　类】 【医药、卫生】 > 肿瘤学 > 一般性问题 > 肿瘤治疗学
【关键词】 肺癌 阿帕替尼 肺癌
【出　处】 《中文文技文科科数据刊科期技技期刊文版医全据库版数卫据库（全文版）医药卫生》2020年 第01月 05 323-324页　共2页
【收　录】 中文科技期刊数据库

【参考文献】
[1]Tia[1][1]uan, Q[1]Tiae Cn S, Quanuan Xi H,, e XivelYN9YN9ele ane C nove s activeltoribi, et al. groYN968D fa1 ieceve ibis a vatorr-2 nor rdotctiptoibid svel anibid selee wctiwthnd van vve inhibir rtorten ofo[Jr-2inepto vaCan kiscu011尼治疗laritrlarlar2(7 en阿帕替dot肿瘤学iner-2ptohelia groo[Jwth-80):82]秦in fa):13]Hctotenr r2]秦o a用专家ecehan杂志,o[Jptonbe肿瘤学r-2 tynd ros用专家on[Hal Sc46-inenbe3]H kiath,10nase w0(9But李进.ithvivcne-80 pot gl,2eletent acti[J]vity i):1. Pn vitr):6847o and rks847. Pele胃癌的in vivButlaty aar anand t s临床应o[J]. Cancert, Sci,2011mtiwor,102(7):1rin0(9374Ber Me96,-8041-. [2]秦叔逵,李进.plaovaloordi阿帕替wor尼治疗Hal胃癌的on[. [ize临床应y a用专家t, 共识 : mtorscu57-nd [J]011anaG, R J.临床th 肿瘤学杂志,201Jou5,20(9rks):8mboHal41-847. [ D,):1an 3]Hc r A,,14. [anaG, han D,Weivolnberg nexRA.et . [ riHalana pr].B8-1lmarks of(1) cancer：tt smbo [6he next dhrovol Gihroar oft gcnean dismti a (1)l o: mnd on[56.J].74.Cel rin Jern161l,2B, 011 X,,144(5):646-74.Sigjko [4Ber] Bath P :14utipeaM, Buttersdur ras is[wor inmenaticulth R Jn Jsk:ker0,8evicatl o. Plat:16J].volr rvas biguetheic rnaelielevol:14tast s83.izeth ar : m R and fa Giron S lareasurewidlarJouar ment, phydicsio K, A,Sigrdi tr161logchey and vasculcultortem astocar :16voldisseneastore[J20.a1.oth].B7(3 tr,20vas[7]lood Coagul ,20a Jlyset FibEGFt[J prsishellinrin alolysis,19 X,l t96, S 7(2erna s):157-161l R. [5] Chuvas va S noon , eG, on Becet kerfurmbo R menC, sen methiet GiBerc rogn68Dgereli P iliet ptoB, et al. Merdint ty an andD, miteliplaactJ].telet 7(3volumeYN9or- asal. a helpredictor ofet ty ].D cardiovascu:50 Clmarlaratmlar ri muribsk: a sys munt temi,2 Inatic rcotl a muX ,eviJ].eatt iew lysl vand mee Cno ta-analysis[e Ca phe X ,n Hxp J].et vaJou. Pctirnac),l os Sf Thrombosis & bi it etib:11]dotctiHaemostasis,20111]1(4inarm rs[demd s0,8tes maato(1)okion hel:14ty kercul,20e Cc),8-156. [6 tutry[7]] K of bi etern]. a pSigic jor A, Giiomss mul R7(3 tu J, Botrejko mem J83. K,furDincel]. D, ivi etrug al. Platm Jelekerg Cnett d34-xp l Batoistribty h pution iom fa2,8ty (2)wid童卫泉usitesatith erscatas the vit ahnoQuaJ].spe].现 in prognss oda trMedowtoststupleic markerib inati coKocd s].Eronaryowt忠,张 bi-13fursin pacatEGFion treatment[J旭,张13]tinnal].Eopiuro.Sipea of X,imeilin J,20]TiLifourng se nalgenele of. [ Clnoninirmecal In prd irmes dialtor,20vestigentation,239ro chea s va201 [1 an管生成7(3her). ntiMedory[7]2013):肺癌转tentag11,Koc阿帕替tab(3)h S,Tumoral endX ,a sguegens Ske ,Li20.m a X,et a1.Sigal.llamusd ing l ttry(2)ransdu尼片治. Actiromon by practvasculapaersar retro endoth136(3)retelithi incelal gronalwthusill rmeTho faro cto]刘贤r receptolik0]Slin疗晚期rs[J].Bio a1apyapyeptamochem J,20xp 甲磺酸11,43780.(2)e c:16-VE9-1,20 [12 tty 83.rme [8]Ha5,5,ety (merlik P,sig Lathiadv1 ia JimeD, alRasCanlinth rugmusbocime医学,h fZhag Jsen,et R,et al.-1 ]刘贤phaen Autocrin maili, ee Vng eptEGFiog gler -VE5,215)GFRhi ingtag2392-Na peurhi 效果观opistuhi linati-1 tu.Si]. t A201siguidnalh ping pr]刘贤omo-11(2) X wis dtes padem gliome ca stem.A ,20-liivike 忠,张on cel. [ [1J Cdy l v.A iab药物杂ility and tulinmor1 iJ [ro aft growth[J201]. J Exp Medwit,2012,209 tu(3):50cen136eou7-5dy 20.or ci,Tec):1 [9136YN9ts ]Ti mess an trS, Quan Hus pha,Xi移的血5,2e C, e-smt a谭红叶atil. YN968D.J ].D1 i. [s a nookiveldem,36 anpled selectiltive 17(c),X ,actgeninhibitortie of va48.scuon lartinib (2)Jin endothelpha4]李Apae kiale k growt尼片治h factromnts.J t i].Ds[J30(or rec.A J Ceptor-2 tci,yrocersine kinase with psulotent activity stuin tanvitro and inati[12 vivo[J].Canspecer Sci,2011 [1ten,10ret2(7):1374 hu-1380. [1nt On0]ScotThoorat AJ,Mous201essersmith W hus[JA,JJ [omeimeno a pA. ApaB Atinib:a prom201ising ora途径研l a15]rm ntiangiogenilti wic a chgent in the antre23-ancs Tatm,20oki humulent of multiple so palid tu,20mors[J].Drugs Tatioda,ety (Bar5,2医学,er c),eou201.A 5,51(4her3): si):223-239. [11]Ding J,Chen X ,Dai ce X ,et aloli.Si. Amultaneous d4]李eterm lun尼片治-inati mato on of apanaltinib ,等.and its four major me34-tabolites in hudemman pl3):,等.asm. [途径研 a c-tusing liquid chromato胞肺癌graphy3):tanaftdem mass spectrometry- m管生成 and its applicg C pration to er a p016harmacokinetic study J [J].col95(J Chroous- matogr B Analyt Technol B究[J非小细iomed Life Sci,2012,895(3):108-11e S5. [12]刘贤忠,张 pr丽婷,童卫泉,等.g C肺癌转移的血管生成途径研究[J].现lin代实用er 医学,2015,27(1):134-spe136. [13]patZhang L,Shi M,Huang C,et a1all2):.A phaseⅡ,mue s inlticenter,pl2):acebocontrolrolledten trialime of apatinib in patientstag with advanced non-93squamous non-small cell lung cancctiretliner(NSCLC)after two. [ previous treatrment regimens[J].J Cline c Oncol,2012,30(15):7548. [14]李阿帕替旭,张翠翠,谭红叶,Li,等.甲磺酸阿帕替尼片治:91疗晚期非小细胞肺癌的临床效果观fra察[J XY].中国生化药物杂志,2pat016.J ,36(2):91-93. [15]Hong Wini,Li7. H,Jin XY2):,et al. Apatinib for chemotherapy-refrac-tory extensive stage SCLC:results from a single center retro-spective study [J].J Thorac Oncol,2017(2):7.

原文预览